Trinity Biotech (TRIB) Asset Writedowns and Impairment (2021 - 2024)
Historic Asset Writedowns and Impairment for Trinity Biotech (TRIB) over the last 4 years, with Q4 2024 value amounting to -$962000.0.
- Trinity Biotech's Asset Writedowns and Impairment fell 23172.41% to -$962000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$1.7 million, marking a year-over-year increase of 4871.93%. This contributed to the annual value of $612000.0 for FY2024, which is 8377.52% down from last year.
- Per Trinity Biotech's latest filing, its Asset Writedowns and Impairment stood at -$962000.0 for Q4 2024, which was down 23172.41% from -$446000.0 recorded in Q2 2024.
- In the past 5 years, Trinity Biotech's Asset Writedowns and Impairment registered a high of $2.3 million during Q3 2022, and its lowest value of -$6.1 million during Q2 2021.
- Over the past 4 years, Trinity Biotech's median Asset Writedowns and Impairment value was -$519000.0 (recorded in 2022), while the average stood at -$1.1 million.
- In the last 5 years, Trinity Biotech's Asset Writedowns and Impairment surged by 10208.38% in 2023 and then tumbled by 422390.2% in 2024.
- Trinity Biotech's Asset Writedowns and Impairment (Quarter) stood at -$876000.0 in 2021, then plummeted by 246.12% to -$3.0 million in 2022, then surged by 90.44% to -$290000.0 in 2023, then tumbled by 231.72% to -$962000.0 in 2024.
- Its Asset Writedowns and Impairment was -$962000.0 in Q4 2024, compared to -$446000.0 in Q2 2024 and -$290000.0 in Q4 2023.